Cognitive Function and White Matter Lesions in Medication-Overuse Headache
This study was designed to investigate the cognitive function and the white matter lesions (WMLs) and the relationship between them in medication-overuse headache (MOH) patients. Subjects were enrolled and performed Montreal Cognitive Assessment (MoCA, Chinese-Beijing Version), Hamilton Anxiety Rati...
Gespeichert in:
| Veröffentlicht in: | Journal of pain research 2021-01, Vol.14, p.1845-1853 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1853 |
|---|---|
| container_issue | |
| container_start_page | 1845 |
| container_title | Journal of pain research |
| container_volume | 14 |
| creator | Xiang, Yue Chen, Shenggen Lin, Hanbin Xiong, Wenting Zheng, Zhenyang |
| description | This study was designed to investigate the cognitive function and the white matter lesions (WMLs) and the relationship between them in medication-overuse headache (MOH) patients.
Subjects were enrolled and performed Montreal Cognitive Assessment (MoCA, Chinese-Beijing Version), Hamilton Anxiety Rating Scale (HAMA), Hamilton Depression Rating Scale (HAMD-24), and Pittsburgh Sleep Quality Index (PSQI) to evaluate the general cognitive function, anxiety, depression and sleep quality, and they were divided into three groups according to the MoCA scores: healthy controls, MOH with normal cognition group and MOH with cognitive impairment group. All the participants underwent MRI scans and images were obtained for WML evaluation with Fazekas scale.
One hundred thirty-four participants were enrolled into this study, 46 of them for healthy controls, and 88 for MOH patients, 40 of the MOH patients for MOH with cognitive impairment group, and 48 for MOH with normal cognition group. MOH patients had significantly lower MoCA scores, including the scores of visuospatial and executive function, attention, and orientation, while they had significantly greater HAMA scores, HAMD-24 scores, PSQI scores, and deep white matter hyperintensity scores compared to healthy controls. And in MOH patients, the age, disease duration, monthly headache days, and periventricular white matter hyperintensity scores in patients with cognitive impairment were greater than those in patients with normal cognition. Moreover, the MoCA scores were negatively related to age, disease duration, monthly headache days, and Fazekas scale scores, and disease duration and monthly headache days were significant predictors of cognitive impairment in MOH patients.
MOH patients showed cognitive impairment and increased WML burden. And in MOH patients, cognitive function was negatively related to WML burden, and disease duration and monthly headache days were potential predictors of cognitive impairment. Prompt and effective treatment to stop the progression of the disease may alleviate cognitive impairment in MOH patients. |
| doi_str_mv | 10.2147/JPR.S310064 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8216749</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A672726906</galeid><sourcerecordid>A672726906</sourcerecordid><originalsourceid>FETCH-LOGICAL-c507t-30bac74c5cb3e57bd41806002c0edee918a8d6c20391bc5e3347b770114076c43</originalsourceid><addsrcrecordid>eNptks1r3DAQxUVpadK0p96LoVACwVt9WbIvgbAkTcOGlH7Qo5Dl2bWCV0oleaH_fWWySXZD0WHEzG-e0OMh9J7gGSVcfr769n32gxGMBX-BDgmRdSlxg1_u3A_QmxhvM1HThrxGB4wTUfOGHqKruV85m-wGiovRmWS9K7Trit-9TVBc65QgFAuIuR8L64pr6KzRE1bebCCMEYpL0J02PbxFr5Z6iPBuW4_Qr4vzn_PLcnHz5ev8bFGaCstUMtxqI7mpTMugkm3HSY0FxtRg6AAaUuu6E4Zi1pDWVMAYl62UmBCOpTCcHaHTe927sV1DZ8CloAd1F-xah7_Ka6v2J872auU3qqZESN5kgeOtQPB_RohJrW00MAzagR-johWvqobWFcnox2forR-Dy9-bKIolqWXzRK30AMq6pc_vmklUnQlJJRUNFpma_YfKp4O1Nd7B0ub-3sKnnYUe9JD66Idxcj_ugyf3oAk-xgDLRzMIVlNGVM6I2mYk0x92_XtkH0LB_gFiLLPs</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2542071879</pqid></control><display><type>article</type><title>Cognitive Function and White Matter Lesions in Medication-Overuse Headache</title><source>Taylor & Francis Open Access</source><source>DOAJ Directory of Open Access Journals</source><source>Dove Press Free</source><source>PubMed Central Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Xiang, Yue ; Chen, Shenggen ; Lin, Hanbin ; Xiong, Wenting ; Zheng, Zhenyang</creator><creatorcontrib>Xiang, Yue ; Chen, Shenggen ; Lin, Hanbin ; Xiong, Wenting ; Zheng, Zhenyang</creatorcontrib><description>This study was designed to investigate the cognitive function and the white matter lesions (WMLs) and the relationship between them in medication-overuse headache (MOH) patients.
Subjects were enrolled and performed Montreal Cognitive Assessment (MoCA, Chinese-Beijing Version), Hamilton Anxiety Rating Scale (HAMA), Hamilton Depression Rating Scale (HAMD-24), and Pittsburgh Sleep Quality Index (PSQI) to evaluate the general cognitive function, anxiety, depression and sleep quality, and they were divided into three groups according to the MoCA scores: healthy controls, MOH with normal cognition group and MOH with cognitive impairment group. All the participants underwent MRI scans and images were obtained for WML evaluation with Fazekas scale.
One hundred thirty-four participants were enrolled into this study, 46 of them for healthy controls, and 88 for MOH patients, 40 of the MOH patients for MOH with cognitive impairment group, and 48 for MOH with normal cognition group. MOH patients had significantly lower MoCA scores, including the scores of visuospatial and executive function, attention, and orientation, while they had significantly greater HAMA scores, HAMD-24 scores, PSQI scores, and deep white matter hyperintensity scores compared to healthy controls. And in MOH patients, the age, disease duration, monthly headache days, and periventricular white matter hyperintensity scores in patients with cognitive impairment were greater than those in patients with normal cognition. Moreover, the MoCA scores were negatively related to age, disease duration, monthly headache days, and Fazekas scale scores, and disease duration and monthly headache days were significant predictors of cognitive impairment in MOH patients.
MOH patients showed cognitive impairment and increased WML burden. And in MOH patients, cognitive function was negatively related to WML burden, and disease duration and monthly headache days were potential predictors of cognitive impairment. Prompt and effective treatment to stop the progression of the disease may alleviate cognitive impairment in MOH patients.</description><identifier>ISSN: 1178-7090</identifier><identifier>EISSN: 1178-7090</identifier><identifier>DOI: 10.2147/JPR.S310064</identifier><identifier>PMID: 34168492</identifier><language>eng</language><publisher>New Zealand: Dove Medical Press Limited</publisher><subject>Age ; Alzheimer's disease ; Cognition ; Cognition & reasoning ; Cognitive ability ; Dementia ; Depression, Mental ; Development and progression ; Diabetes ; Drug therapy ; Headache ; Headaches ; Hospitals ; Hypertension ; Neuropsychology ; Original Research ; Risk factors ; Sleep ; Smoking ; Statistical analysis</subject><ispartof>Journal of pain research, 2021-01, Vol.14, p.1845-1853</ispartof><rights>2021 Xiang et al.</rights><rights>COPYRIGHT 2021 Dove Medical Press Limited</rights><rights>2021. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 Xiang et al. 2021 Xiang et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c507t-30bac74c5cb3e57bd41806002c0edee918a8d6c20391bc5e3347b770114076c43</citedby><cites>FETCH-LOGICAL-c507t-30bac74c5cb3e57bd41806002c0edee918a8d6c20391bc5e3347b770114076c43</cites><orcidid>0000-0003-4382-3317</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216749/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216749/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,3862,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34168492$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Xiang, Yue</creatorcontrib><creatorcontrib>Chen, Shenggen</creatorcontrib><creatorcontrib>Lin, Hanbin</creatorcontrib><creatorcontrib>Xiong, Wenting</creatorcontrib><creatorcontrib>Zheng, Zhenyang</creatorcontrib><title>Cognitive Function and White Matter Lesions in Medication-Overuse Headache</title><title>Journal of pain research</title><addtitle>J Pain Res</addtitle><description>This study was designed to investigate the cognitive function and the white matter lesions (WMLs) and the relationship between them in medication-overuse headache (MOH) patients.
Subjects were enrolled and performed Montreal Cognitive Assessment (MoCA, Chinese-Beijing Version), Hamilton Anxiety Rating Scale (HAMA), Hamilton Depression Rating Scale (HAMD-24), and Pittsburgh Sleep Quality Index (PSQI) to evaluate the general cognitive function, anxiety, depression and sleep quality, and they were divided into three groups according to the MoCA scores: healthy controls, MOH with normal cognition group and MOH with cognitive impairment group. All the participants underwent MRI scans and images were obtained for WML evaluation with Fazekas scale.
One hundred thirty-four participants were enrolled into this study, 46 of them for healthy controls, and 88 for MOH patients, 40 of the MOH patients for MOH with cognitive impairment group, and 48 for MOH with normal cognition group. MOH patients had significantly lower MoCA scores, including the scores of visuospatial and executive function, attention, and orientation, while they had significantly greater HAMA scores, HAMD-24 scores, PSQI scores, and deep white matter hyperintensity scores compared to healthy controls. And in MOH patients, the age, disease duration, monthly headache days, and periventricular white matter hyperintensity scores in patients with cognitive impairment were greater than those in patients with normal cognition. Moreover, the MoCA scores were negatively related to age, disease duration, monthly headache days, and Fazekas scale scores, and disease duration and monthly headache days were significant predictors of cognitive impairment in MOH patients.
MOH patients showed cognitive impairment and increased WML burden. And in MOH patients, cognitive function was negatively related to WML burden, and disease duration and monthly headache days were potential predictors of cognitive impairment. Prompt and effective treatment to stop the progression of the disease may alleviate cognitive impairment in MOH patients.</description><subject>Age</subject><subject>Alzheimer's disease</subject><subject>Cognition</subject><subject>Cognition & reasoning</subject><subject>Cognitive ability</subject><subject>Dementia</subject><subject>Depression, Mental</subject><subject>Development and progression</subject><subject>Diabetes</subject><subject>Drug therapy</subject><subject>Headache</subject><subject>Headaches</subject><subject>Hospitals</subject><subject>Hypertension</subject><subject>Neuropsychology</subject><subject>Original Research</subject><subject>Risk factors</subject><subject>Sleep</subject><subject>Smoking</subject><subject>Statistical analysis</subject><issn>1178-7090</issn><issn>1178-7090</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptks1r3DAQxUVpadK0p96LoVACwVt9WbIvgbAkTcOGlH7Qo5Dl2bWCV0oleaH_fWWySXZD0WHEzG-e0OMh9J7gGSVcfr769n32gxGMBX-BDgmRdSlxg1_u3A_QmxhvM1HThrxGB4wTUfOGHqKruV85m-wGiovRmWS9K7Trit-9TVBc65QgFAuIuR8L64pr6KzRE1bebCCMEYpL0J02PbxFr5Z6iPBuW4_Qr4vzn_PLcnHz5ev8bFGaCstUMtxqI7mpTMugkm3HSY0FxtRg6AAaUuu6E4Zi1pDWVMAYl62UmBCOpTCcHaHTe927sV1DZ8CloAd1F-xah7_Ka6v2J872auU3qqZESN5kgeOtQPB_RohJrW00MAzagR-johWvqobWFcnox2forR-Dy9-bKIolqWXzRK30AMq6pc_vmklUnQlJJRUNFpma_YfKp4O1Nd7B0ub-3sKnnYUe9JD66Idxcj_ugyf3oAk-xgDLRzMIVlNGVM6I2mYk0x92_XtkH0LB_gFiLLPs</recordid><startdate>20210101</startdate><enddate>20210101</enddate><creator>Xiang, Yue</creator><creator>Chen, Shenggen</creator><creator>Lin, Hanbin</creator><creator>Xiong, Wenting</creator><creator>Zheng, Zhenyang</creator><general>Dove Medical Press Limited</general><general>Taylor & Francis Ltd</general><general>Dove</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7XB</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-4382-3317</orcidid></search><sort><creationdate>20210101</creationdate><title>Cognitive Function and White Matter Lesions in Medication-Overuse Headache</title><author>Xiang, Yue ; Chen, Shenggen ; Lin, Hanbin ; Xiong, Wenting ; Zheng, Zhenyang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c507t-30bac74c5cb3e57bd41806002c0edee918a8d6c20391bc5e3347b770114076c43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Age</topic><topic>Alzheimer's disease</topic><topic>Cognition</topic><topic>Cognition & reasoning</topic><topic>Cognitive ability</topic><topic>Dementia</topic><topic>Depression, Mental</topic><topic>Development and progression</topic><topic>Diabetes</topic><topic>Drug therapy</topic><topic>Headache</topic><topic>Headaches</topic><topic>Hospitals</topic><topic>Hypertension</topic><topic>Neuropsychology</topic><topic>Original Research</topic><topic>Risk factors</topic><topic>Sleep</topic><topic>Smoking</topic><topic>Statistical analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Xiang, Yue</creatorcontrib><creatorcontrib>Chen, Shenggen</creatorcontrib><creatorcontrib>Lin, Hanbin</creatorcontrib><creatorcontrib>Xiong, Wenting</creatorcontrib><creatorcontrib>Zheng, Zhenyang</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of pain research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Xiang, Yue</au><au>Chen, Shenggen</au><au>Lin, Hanbin</au><au>Xiong, Wenting</au><au>Zheng, Zhenyang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cognitive Function and White Matter Lesions in Medication-Overuse Headache</atitle><jtitle>Journal of pain research</jtitle><addtitle>J Pain Res</addtitle><date>2021-01-01</date><risdate>2021</risdate><volume>14</volume><spage>1845</spage><epage>1853</epage><pages>1845-1853</pages><issn>1178-7090</issn><eissn>1178-7090</eissn><abstract>This study was designed to investigate the cognitive function and the white matter lesions (WMLs) and the relationship between them in medication-overuse headache (MOH) patients.
Subjects were enrolled and performed Montreal Cognitive Assessment (MoCA, Chinese-Beijing Version), Hamilton Anxiety Rating Scale (HAMA), Hamilton Depression Rating Scale (HAMD-24), and Pittsburgh Sleep Quality Index (PSQI) to evaluate the general cognitive function, anxiety, depression and sleep quality, and they were divided into three groups according to the MoCA scores: healthy controls, MOH with normal cognition group and MOH with cognitive impairment group. All the participants underwent MRI scans and images were obtained for WML evaluation with Fazekas scale.
One hundred thirty-four participants were enrolled into this study, 46 of them for healthy controls, and 88 for MOH patients, 40 of the MOH patients for MOH with cognitive impairment group, and 48 for MOH with normal cognition group. MOH patients had significantly lower MoCA scores, including the scores of visuospatial and executive function, attention, and orientation, while they had significantly greater HAMA scores, HAMD-24 scores, PSQI scores, and deep white matter hyperintensity scores compared to healthy controls. And in MOH patients, the age, disease duration, monthly headache days, and periventricular white matter hyperintensity scores in patients with cognitive impairment were greater than those in patients with normal cognition. Moreover, the MoCA scores were negatively related to age, disease duration, monthly headache days, and Fazekas scale scores, and disease duration and monthly headache days were significant predictors of cognitive impairment in MOH patients.
MOH patients showed cognitive impairment and increased WML burden. And in MOH patients, cognitive function was negatively related to WML burden, and disease duration and monthly headache days were potential predictors of cognitive impairment. Prompt and effective treatment to stop the progression of the disease may alleviate cognitive impairment in MOH patients.</abstract><cop>New Zealand</cop><pub>Dove Medical Press Limited</pub><pmid>34168492</pmid><doi>10.2147/JPR.S310064</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-4382-3317</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1178-7090 |
| ispartof | Journal of pain research, 2021-01, Vol.14, p.1845-1853 |
| issn | 1178-7090 1178-7090 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8216749 |
| source | Taylor & Francis Open Access; DOAJ Directory of Open Access Journals; Dove Press Free; PubMed Central Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Age Alzheimer's disease Cognition Cognition & reasoning Cognitive ability Dementia Depression, Mental Development and progression Diabetes Drug therapy Headache Headaches Hospitals Hypertension Neuropsychology Original Research Risk factors Sleep Smoking Statistical analysis |
| title | Cognitive Function and White Matter Lesions in Medication-Overuse Headache |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T04%3A57%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cognitive%20Function%20and%20White%20Matter%20Lesions%20in%20Medication-Overuse%20Headache&rft.jtitle=Journal%20of%20pain%20research&rft.au=Xiang,%20Yue&rft.date=2021-01-01&rft.volume=14&rft.spage=1845&rft.epage=1853&rft.pages=1845-1853&rft.issn=1178-7090&rft.eissn=1178-7090&rft_id=info:doi/10.2147/JPR.S310064&rft_dat=%3Cgale_pubme%3EA672726906%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2542071879&rft_id=info:pmid/34168492&rft_galeid=A672726906&rfr_iscdi=true |